Ultragenyx Pharmaceutical Inc. (RARE) Earnings
|
Expand Research on RARE
| Next EPS Date | 8/5/26 *Est. | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -14.4% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -2.5% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
4/30/26  |
Q126 | N/A | -$1.43 | N/A | N/A | $164.38M | = | N/A | N/A | ||
| 2/12/26 | Q425 | -$1.29 | -$1.15 | -$0.14 | $207M | $192.15M | = |  | | Details | |
| 11/4/25 | Q325 | -$1.81 | -$1.23 | -$0.58 | $160M | $167M | = | | | Details | |
| 8/5/25 |
Q225 | N/A | -$1.30 | N/A | N/A | $161.97M | = | N/A | N/A | ||
| 5/6/25 |
Q125 | N/A | -$1.56 | N/A | $139M | $145.39M | = | N/A | N/A | ||
| 5/1/25 |
Q125 | N/A | -$1.56 | N/A | N/A | $145.39M | = | N/A | N/A | ||
| 2/13/25 | Q424 | -$1.39 | -$1.34 | -$0.05 | $164.88M | $146.59M | = | | | Details | |
| 11/5/24 | Q324 | -$1.40 | -$1.48 | +$0.08 | $139.45M | $135.28M | = | | | Details |
